February 29, 2024

JHVEPhoto

Pfizer Inc. (NYSE:PFE) inventory has continued to reel from the exhaustion of COVID {dollars}. Particularly, the 2023 downturn has been primarily dragged by a faster-than-expected normalization of Comirnaty vaccine and Paxlovid COVID therapy uptakes. Along with the $5.6 billion write-offsteerage